XTL Biopharmaceuticals Ltd. (XTLB) Balance Sheet
XTLB balance sheet, 2025
December 31, 2025 · U.S. dollars$166,000 assets = $420,000 liabilities + −$254,000 equity
Liabilities exceed assets: shareholders’ equity is negative (−$254,000).
Both columns are drawn to the same scale: what XTLB owns equals what it owes plus shareholders’ equity. Hover a block for its value.
XTLB financial health
Descriptive bands, not a rating. Fiscal 2025.
XTLB balance sheet trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $3.0M2016 | $166,0002025 | −27.5%/yr | |
| Total liabilities | $330,0002016 | $420,0002025 | +2.7%/yr | |
| Shareholders’ equity | $2.7M2016 | −$254,0002025 | — | |
| Cash & short-term investments | $2.4M2016 | $144,0002025 | −27.0%/yr | |
| Total debt | $138,0002024 | $269,0002025 | +94.9%/yr | |
| Net cash (debt) | $1.0M2024 | −$125,0002025 | −$1.1M | |
| Working capital | $2.4M2016 | −$254,0002025 | −$2.7M | |
| Current ratio | 8.352016 | 0.402025 | −7.95 |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
XTLB assets
XTLB liabilities and equity
XTLB debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
XTLB balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $144,000 | $1.1M | $2.0M | $3.7M | $6.1M | $6.0M | $6.7M | $8.1M | $6.1M | $2.4M |
| Cash & equivalents | $76,000 | $371,000 | $1.4M | $2.1M | $3.0M | $3.6M | $4.5M | $3.3M | $3.3M | $2.0M |
| Short-term investments | $68,000 | $772,000 | $605,000 | $1.6M | $3.2M | $2.4M | $2.3M | $4.9M | $2.8M | $414,000 |
| Receivables | $0 | $99,000 | $29,000 | $71,000 | $94,000 | $0 | $0 | $22,000 | $12,000 | $12,000 |
| Inventory | $0 | $0 | −$29,000 | $0 | $0 | $0 | $0 | −$22,000 | $85,000 | $130,000 |
| Other current assets | $22,000 | $98,000 | $40,000 | $14,000 | $16,000 | $79,000 | $102,000 | $73,000 | $15,000 | $179,000 |
| Total current assets | $166,000 | $1.3M | $2.0M | $3.8M | $6.2M | $6.1M | $6.8M | $8.2M | $6.2M | $2.8M |
| Property, plant & equipment (net) | $0 | $187,000 | $0 | $0 | $1,000 | $2,000 | $2,000 | $0 | $0 | $10,000 |
| Goodwill & intangible assets | $0 | $7.0M | $380,000 | $380,000 | $380,000 | $380,000 | $380,000 | $380,000 | $380,000 | $253,000 |
| Long-term investments | $0 | $14,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total assets | $166,000 | $8.6M | $2.4M | $4.2M | $6.6M | $6.5M | $7.2M | $8.6M | $6.6M | $3.0M |
| Liabilities | ||||||||||
| Accounts payable | $20,000 | $196,000 | $1,000 | $2,000 | $2,000 | $2,000 | $1,000 | $253,000 | $4,000 | $17,000 |
| Short-term debt | $269,000 | $138,000 | — | — | — | — | — | — | — | — |
| Deferred revenue | — | $18,000 | — | — | — | — | — | — | — | — |
| Total current liabilities | $420,000 | $2.2M | $206,000 | $187,000 | $231,000 | $254,000 | $232,000 | $253,000 | $300,000 | $330,000 |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other long-term liabilities | $0 | $908,000 | $0 | $2,000 | $1.1M | $2.6M | $465,000 | $0 | $2.7M | $17,000 |
| Total liabilities | $420,000 | $3.1M | $206,000 | $187,000 | $1.3M | $254,000 | $232,000 | $253,000 | $3.0M | $330,000 |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | $25.1M | $23.1M | $14.1M | $14.1M | $14.1M | $13.2M | $13.2M | $13.2M | $13.2M | $6.6M |
| Retained earnings (deficit) | −$165.6M | −$159.0M | −$158.2M | −$156.5M | −$155.1M | −$155.6M | −$153.9M | −$152.6M | −$155.6M | −$154.9M |
| Accumulated other comprehensive income | $20,000 | $20,000 | $20,000 | $20,000 | $20,000 | $20,000 | $20,000 | $20,000 | $67,000 | $183,000 |
| Total shareholders' equity | −$254,000 | $5.4M | $2.2M | $4.0M | $5.3M | $3.6M | $7.0M | $8.3M | $3.6M | $2.7M |
| Key figures | ||||||||||
| Total debt | $269,000 | $138,000 | — | — | — | — | — | — | — | — |
| Net cash (debt) | −$125,000 | $1.0M | — | — | — | — | — | — | — | — |
| Working capital | −$254,000 | −$867,000 | $1.8M | $3.6M | $6.0M | $5.9M | $6.6M | $7.9M | $5.9M | $2.4M |
| Tangible book value | −$254,000 | −$1.6M | $1.8M | $3.6M | $5.0M | $3.2M | $6.6M | $7.9M | $3.2M | $2.4M |
| Current ratio | 0.40 | 0.61 | 9.93 | 20.35 | 27.00 | 24.10 | 29.44 | 32.39 | 20.69 | 8.35 |
| Quick ratio | 0.34 | 0.56 | 9.88 | 20.28 | 26.93 | 23.79 | 29.00 | 32.19 | 20.35 | 7.41 |
| Debt / equity | — | 0.03 | — | — | — | — | — | — | — | — |
| Equity / assets | −153.0% | 63.6% | 91.5% | 95.5% | 80.6% | 55.5% | 96.8% | 97.0% | 54.9% | 89.1% |
| Mar '26 | Dec '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $144,000 | $144,000 | $259,000 | $1.1M | $1.1M | $1.7M | $1.6M | $2.3M | $2.0M | $2.2M | $2.4M | $2.9M |
| Cash & equivalents | $76,000 | $76,000 | $150,000 | $371,000 | $371,000 | $820,000 | $594,000 | $1.1M | $1.4M | $1.5M | $1.6M | $1.9M |
| Short-term investments | $68,000 | $68,000 | $109,000 | $772,000 | $772,000 | $900,000 | $992,000 | $1.3M | $605,000 | $749,000 | $794,000 | $972,000 |
| Receivables | $0 | $0 | $90,000 | $99,000 | $99,000 | $140,000 | $304,000 | $150,000 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $22,000 | $22,000 | $184,000 | $98,000 | $98,000 | $127,000 | $128,000 | $59,000 | $40,000 | $77,000 | $118,000 | $66,000 |
| Total current assets | $166,000 | $166,000 | $533,000 | $1.3M | $1.3M | $2.0M | $2.0M | $2.5M | $2.0M | $2.3M | $2.5M | $2.9M |
| Property, plant & equipment (net) | $0 | $0 | $167,000 | $187,000 | $187,000 | $217,000 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill & intangible assets | $0 | $0 | $0 | $7.0M | $7.0M | $7.1M | $380,000 | $380,000 | $380,000 | $380,000 | $380,000 | $380,000 |
| Long-term investments | $0 | $0 | $14,000 | $0 | $14,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $0 | $0 | $14,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total assets | $166,000 | $166,000 | $714,000 | $8.6M | $8.6M | $9.3M | $2.4M | $2.9M | $2.4M | $2.7M | $2.9M | $3.3M |
| Liabilities | ||||||||||||
| Accounts payable | $20,000 | $20,000 | $638,000 | $196,000 | $196,000 | $554,000 | $165,000 | $223,000 | $1,000 | $162,000 | $163,000 | $241,000 |
| Short-term debt | $269,000 | — | — | $138,000 | — | $168,000 | — | — | — | — | — | — |
| Deferred revenue | — | — | — | $18,000 | — | — | — | — | — | — | — | — |
| Total current liabilities | $420,000 | $420,000 | $761,000 | $2.2M | $2.2M | $2.5M | $165,000 | $223,000 | $206,000 | $162,000 | $163,000 | $241,000 |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other long-term liabilities | $0 | $0 | $0 | $908,000 | $908,000 | $1.1M | $0 | $0 | $0 | $0 | $0 | $241,000 |
| Total liabilities | $420,000 | $420,000 | $761,000 | $3.1M | $3.1M | $3.6M | $165,000 | $223,000 | $206,000 | $162,000 | $163,000 | $241,000 |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $25.1M | — | — | $23.1M | — | $23.1M | $14.1M | $14.1M | $14.1M | $14.1M | $14.1M | $14.1M |
| Retained earnings (deficit) | −$165.6M | −$165.6M | −$164.5M | −$159.0M | −$159.0M | −$158.8M | −$158.2M | −$157.8M | −$158.2M | −$158.0M | −$157.7M | −$157.4M |
| Accumulated other comprehensive income | $20,000 | — | — | $20,000 | — | $20,000 | $20,000 | $20,000 | $20,000 | $20,000 | $20,000 | $20,000 |
| Total shareholders' equity | −$254,000 | −$254,000 | −$47,000 | $5.4M | $5.4M | $5.7M | $2.2M | $2.7M | $2.2M | $2.5M | $2.7M | $3.1M |
| Key figures | ||||||||||||
| Total debt | $269,000 | — | — | $138,000 | — | $168,000 | — | — | — | — | — | — |
| Net cash (debt) | −$125,000 | — | — | $1.0M | — | $1.6M | — | — | — | — | — | — |
| Working capital | −$254,000 | −$254,000 | −$228,000 | −$867,000 | −$867,000 | −$480,000 | $1.9M | $2.3M | $1.8M | $2.1M | $2.3M | $2.7M |
| Tangible book value | −$254,000 | −$254,000 | −$47,000 | −$1.6M | −$1.6M | −$1.4M | $1.9M | $2.3M | $1.8M | $2.1M | $2.3M | $2.7M |
| Book value per share | — | — | — | — | — | — | — | — | $0.41 | — | — | — |
| Shares outstanding | — | — | — | — | — | — | — | — | 5.4M | — | — | — |
| Current ratio | 0.40 | 0.40 | 0.70 | 0.61 | 0.61 | 0.81 | 12.23 | 11.43 | 9.93 | 14.09 | 15.34 | 12.21 |
| Quick ratio | 0.34 | 0.34 | 0.46 | 0.56 | 0.56 | 0.75 | 11.45 | 11.16 | 9.74 | 13.62 | 14.62 | 11.93 |
| Debt / equity | — | — | — | 0.03 | — | 0.03 | — | — | — | — | — | — |
| Equity / assets | −153.0% | −153.0% | −6.6% | 63.6% | 63.6% | 61.6% | 93.1% | 92.4% | 91.5% | 93.9% | 94.3% | 92.7% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed June 30, 2026); data from EODHD.
XTLB financial position
At the end of fiscal 2025 (December 31, 2025), XTL Biopharmaceuticals had total assets of $0.2 million (down 98.1% from a year earlier), total liabilities of $0.4 million and shareholders' equity of -$0.3 million. It held $0.1 million in cash and short-term investments against $0.3 million of debt, net debt of $0.1 million. Its current ratio was 0.40. In the latest quarter (ended March 31, 2026) total assets were $0.2 million and equity -$0.3 million.
Related: XTLB income statement, XTLB cash flow statement, XTLB key metrics. See the XTLB stock overview for the latest quote and news.
XTLB balance sheet FAQ
What are XTL Biopharmaceuticals's total assets?
XTL Biopharmaceuticals reported total assets of $0.2 million at the end of fiscal 2025 (December 31, 2025), compared with $8.6 million a year earlier.
How much debt does XTL Biopharmaceuticals have?
XTL Biopharmaceuticals had $0.3 million of total debt at the end of fiscal 2025, including short-term borrowings. Its debt-to-equity ratio was —.
How much cash does XTL Biopharmaceuticals have?
XTL Biopharmaceuticals held $0.1 million in cash and short-term investments at the end of fiscal 2025; with $0.3 million of debt that is net debt of $0.1 million.
What is XTL Biopharmaceuticals's book value?
XTL Biopharmaceuticals's shareholders' equity (book value) was -$0.3 million at the end of fiscal 2025.
What is XTL Biopharmaceuticals's current ratio?
XTL Biopharmaceuticals had current assets of $0.2 million and current liabilities of $0.4 million, a current ratio of 0.40 (current liabilities exceed current assets).